Detected ·
Neurimmune AG
$425M—
Neurimmune AG, a Swiss biotech, has secured a royalty financing agreement worth up to USD 425 million with Royalty Pharma to accelerate its R&D pipeline, backed by the future commercial potential of cliramitug, an investigational therapy for transthyretin amyloid cardiomyopathy (ATTR-CM) in Phase 3 development.
- Website
- www.neurimmune.com
- linkedin.com/company/neurimmune
- Amount
- $425 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-23 12:05:13 UTC
- Signal ID
- 2ea7ceb6-89fd-41fd-bc87-1f941fccf359
As the API returns it
{
"id": "2ea7ceb6-89fd-41fd-bc87-1f941fccf359",
"created_at": "2026-07-23T12:05:13.223186Z",
"company_name": "Neurimmune AG",
"company_website_url": "www.neurimmune.com",
"company_linkedin_url": "https://www.linkedin.com/company/neurimmune",
"event_type": "funding",
"funding_amount": 425000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Neurimmune AG, a Swiss biotech, has secured a royalty financing agreement worth up to USD 425 million with Royalty Pharma to accelerate its R&D pipeline, backed by the future commercial potential of cliramitug, an investigational therapy for transthyretin amyloid cardiomyopathy (ATTR-CM) in Phase 3 development.*"
}